Abstract
THE Epstein–Barr virus (EBV)-encoded nuclear antigen (EBNA1) is expressed in latently EBV-infected B lymphocytes that persist for life in healthy virus carriers1,2, and is the only viral protein regularly detected in all malignancies associated with EBV3,4. Major histocompatibility complex (MHC) class I-restricted, EBNA1-specific cytotoxic T lymphocyte (CTL) responses have not been demonstrated3,5. Using recombinant vaccinia viruses encoding chimaeric proteins containing an immunodominant human leukocyte antigen All-restricted CTL epitope, amino acids 416–424 of the EBNA4 protein6, inserted within the intact EBNA1, or within an EBNA1 deletion mutant devoid of the internal Gly–Ala repetitive sequence, we demonstrate that the Gly–Ala repeats generate a cis-acting inhibitory signal that interferes with antigen processing and MHC class I-restricted presentation. Insertion of the Gly–Ala repeats downstream of the 416–424 epitope inhibited CTL recognition of a chimaeric EBNA4 protein. The results highlight a previously unknown mechanism of viral escape from CTL surveillance, and support the view that the resistance of cells expressing EBNA1 to rejection mediated by CTL is a critical requirement for EBV persistence and pathogenesis.
Article PDF
References
Tierney, R. J., Steven, N., Young, L. S. & Rickinson, A. B. J. Virol. 68, 7374–7385 (1994).
Chen, F. et al. J. Virol (in the press).
Masucci, M. G. & Ernberg, I. Trends Microbiol. 2, 125–130 (1994).
Klein, G. Cell 77, 791–793 (1994).
Rickinson, A. et al. in A New Look at Tumor Immunology (eds McMichael, A. & Franks, L.) 53–80 (Cold Spring Harbor Laboratory Press, New York, 1992).
Gavioli, R. et al. J. Virol. 67, 1572–1578 (1993).
Rawlins, D. R., Milman, G., Hayward, D. S. & Haywards, G. S. Cell 42, 859–868 (1985).
Baer, R. et al. Nature 310, 207–211 (1984).
Dillner, J. et al. Proc. natn. Acad. Sci. U.S.A. 81, 4652–4656 (1984).
de Campos-Lima, P. O. et al. J. exp. Med. 179, 1297–1305 (1994).
Steigewald-Mullen, P. M. & Kurilla, M. G. J. gen. Virol. (in the press).
Bangham, C. R. M. et al. J. Immun. 137, 3973–3977 (1986).
Lee, P. & Hruby, D. E. J. Virol. 67, 4252–4263 (1993).
Murray, R. et al. J. exp. Med. 176, 157–168 (1992).
Michalek, M. T., Grant, E. P., Gramm, C., Goldberg, A. L. & Rock, K. L. Nature 363, 552–554 (1993).
Rock, K. L. et al. Cell 78, 761–771 (1994).
Ciechanover, A. Cell 79, 13–21 (1994).
Tsubota, H., Lord, C. I., Watkins, D. I., Morimoto, C. & Letvin, N. L. J. exp. Med. 169, 1421–1434 (1989).
Lukacher, A. E., Braciale, V. L. & Braciale, T. J. J. exp. Med. 160, 814–826 (1984).
Byrne, J. A. & Oldstone, M. B. A. J. Virol. 51, 682–686 (1984).
Burgert, H. G., Maryansky, J. L. & Kvist, S. Proc. natn. Acad. Sci. U.S.A. 84, 1356–1359 (1987).
Phillips, R. et al. Nature 354, 453–459 (1991).
Pircher, H. et al. Nature 346, 629–633 (1990).
Klenerman, P. et al. Nature 369, 403–407 (1994).
Bertoletti, A. et al. Nature 369, 407–410 (1994).
Tishon, A., Borrow, P., Evans, C. & A., O. M. B. Virology 195, 397–405 (1993).
Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Nature 362, 758–761 (1993).
Reedman, B. M. & Klein, G. Int. J. Cancer 11, 499–520 (1973).
Chen, M.-R., Middletorp, J. M. & Hayward, D. J. Virol. 67, 4875–4885 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levitskaya, J., Coram, M., Levitsky, V. et al. Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature 375, 685–688 (1995). https://doi.org/10.1038/375685a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/375685a0
This article is cited by
-
Exploring the link between viruses and cancer in companion animals: a comprehensive and comparative analysis
Infectious Agents and Cancer (2023)
-
Epstein–Barr virus and multiple sclerosis
Nature Reviews Microbiology (2023)
-
The lytic phase of Epstein–Barr virus plays an important role in tumorigenesis
Virus Genes (2023)
-
SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis
Nature Communications (2021)
-
The molecular march of primary and recurrent nasopharyngeal carcinoma
Oncogene (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
